Kineta

Announcing that @kinetabio has reopened enrollment for our VISTA-101 Clinical Trial Evaluating KVA12123 and a combination arm utilizing KVA12123 together with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) kinetabio.com/2024/08/19/kin…

Don’t Miss It! Join the 3rd Annual VISTA Symposium on Weds, March 27 at 11am ET, where renowned scientific experts will explore the important role of VISTA in #cancer #immunotherapy. Co-hosted by @kinetabio ($KA), @hummingbirdbio @geiselmed Register: lifescievents.com/events/vistasy…

Come see and meet with @kinetabio at several upcoming investor conferences including @IAmBiotech #BIOCEO, #IO360NYC and @Opal_Group Family Office Winter Forum. kinetabio.com/2024/02/14/kin…

Join @kinetabio and @HCWCO tomorrow Feb 13 at 11:00AM EST/8:00AM PST for a virtual presentation on KVA12123 and fireside chat with HC Wainwright Senior Healthcare Analyst Robert Burns. Register: journey.ct.events/view/82735925-… kinetabio.com/2024/02/07/kin…

Join @kinetabio's CEO Shawn Iadonato and CSO Thierry Guillaudeux for a virtual presentation on KVA12123 and fireside chat with @HCWCO Senior Healthcare Analyst Robert Burns on February 13th at 11:00AM Eastern. Register: journey.ct.events/view/82735925-… kinetabio.com/2024/02/07/kin…

@kinetabio provides update on its ongoing Phase 1/2 VISTA-101 #clinicaltrial of KVA12123 in patients with advanced #solidtumors #immunotherapy #immunooncology #cancer kinetabio.com/2024/01/17/kin…

Meet with the @kinetabio management team during the @LifeSciAdvisors corporate access event on Jan 8-9 in San Francisco during #JPMWeek. Register here: meetmax.com/sched/event_10… #JPM24 #JPM2024 kinetabio.com/2024/01/04/kin…

@kinetabio publishes preclinical data of VISTA blocking #antibody KVA12123 in Frontiers in #Immunology #Immunotherapy #immunooncology #Cancer kinetabio.com/2023/12/13/kin…

Join @kinetabio CEO Shawn Iadonato and @ZacksResearch Senior Analyst @vanjohn10 for a "CEO Chat" webinar hosted by @RIConferences this Thursday Dec 14th at 11:30 A.M. Eastern. LINK: bit.ly/3FgGsBt globenewswire.com/news-release/2…

New article from @TargetedOnc on KVA12123 targetedonc.com/view/kva12123-…

ICYMI: The virtual KOL event hosted by @KinetaBio ($KA) is now available for replay! The event features Michael Curran, PhD (MD Anderson) and Evan Yu, MD (Fred Hutch), who review new data from VISTA-101 clinical trial of KVA12123. Register: lifescievents.com/event/kineta/

Join @KinetaBio (#KA) TODAY at 2pm ET for a virtual KOL event, feat. Michael A. Curran, PhD (MD Anderson Cancer Center) and Evan Y. Yu, MD (Fred Hutch Cancer Center), who will review New Data from VISTA-101 clinical trial of KVA12123. Register: lifescievents.com/event/kineta/

Gary Gentges and Thierry Guillaudeux gave great insight on how to enter the public market and build a best in class biotech company. #OpalGroup #OpalGroupAIS #BioTech

Join @KinetaBio (#KA) for a virtual KOL event on Dec. 5 at 2pm ET, feat. Michael A. Curran, PhD (MD Anderson Cancer Center) and Evan Y. Yu, MD (Fred Hutch Cancer Center), who will review New Data from VISTA-101 clinical trial of KVA12123. Register: lifescievents.com/event/kineta/

@kinetabio unveils positive new data from our VISTA-101 #Clinicaltrial of KVA12123 at #SITC2023. Click on the link below to see the PR and poster presentation. #Immunotherapy #immunooncology #oncology #Cancer #SITC2023 kinetabio.com/2023/11/06/kin…

Stop by to see @kinetabio Chief Scientific Officer Thierry Guillaudeux present our KVA12123 VISTA-101 Phase 1/2 clinical trial update at #sitc2023 today! Abstract/Poster #780 in Exhibit Hall B #immunooncology #immunotherapy #cancer #clinicaltrials

@kinetabio CSO Thierry Guillaudeux presents new preclinical data on our lead anti-CD27 antibody at #SITC2023 #immunooncology #immunotherapy #cancer kinetabio.com/2023/11/03/kin…